Palliation of Metastatic Gastric Cancer: Impact of Preoperative Symptoms and the Type of Operation on Survival and Quality of Life

2004 ◽  
Vol 28 (4) ◽  
pp. 369-375 ◽  
Author(s):  
Volker Kahlke ◽  
Julius Marek Doniec ◽  
Thomas K�chler ◽  
Bernd Kremer ◽  
Andreas Schmid ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Metastatic Gastric Cancer

scholarly journals Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS

2020 ◽  
Vol 23 (4) ◽  
pp. 689-698 ◽  
Author(s):  
Josep Tabernero ◽  
Maria Alsina ◽  
Kohei Shitara ◽  
Toshihiko Doi ◽  
Mikhail Dvorkin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Health Related Quality ◽  
Related Quality ◽  
Heavily Pretreated ◽  
Health Related

scholarly journals Comparison of health-related quality of life with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil chemotherapy regimens as first-line systemic therapy in locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma: A prospective study from South India

2018 ◽  
Vol 07 (01) ◽  
pp. 11-15
Author(s):  
K. Govind Babu ◽  
Tamojit Chaudhuri ◽  
K. C. Lakshmaiah ◽  
Lokanatha Dasappa ◽  
Linu Abraham Jacob ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Prospective Study ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Health Related Quality ◽  
First Line ◽  
Related Quality ◽  
Health Related

Abstract Background: Health-related quality of life (HRQOL) is an important oncologic end point for upper gastrointestinal malignancies. Unfortunately, till date, there is no published prospective data from India, comparing the HRQOL parameters between first-line chemotherapy regimens in advanced/metastatic gastric cancer. Materials and Methods: The present study aimed to compare the HRQOL of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-FU (ECF) and docetaxel, cisplatin plus 5-FU (DCF) regimens in patients with locally advanced inoperable or metastatic gastric or gastro-esophageal junction adenocarcinoma. The secondary end points were overall response rate, progression-free survival (PFS), overall survival (OS), and toxicity profile. Results: Between December 2014 and December 2016, 65 patients were treated with ECF (n= 34) or DCF (n= 31) regimen. The baseline HRQOL scores were comparable between the two study groups, with the exception of significantly poor pain and sleep difficulties symptom score in the DCF group. After three cycles of treatment, both the groups showed improvements in most of the quality of life (QOL) parameters including global QOL score, compared with their baseline status. After six cycles of chemotherapy, the ECF group showed nonsignificant deterioration for most of the QOL parameters; but on the contrary, the DCF group maintained improved scores for most of the QOL parameters. The median survival until a definitive deterioration of global QOL score was significantly better in the DCF arm in comparison to the ECF arm (7.1 vs. 5.6 months, respectively, P = 0.000). The median OS was 9.2 months with ECF and 12.5 months with DCF regimen (P = 0.000), while median PFS was 5.7 and 7.4 months with ECF and DCF regimens, respectively (P = 0.002). Conclusions: This prospective study highlighted a better impact of DCF chemotherapy on the HRQOL of patients with advanced/metastatic gastric cancer and showed the importance of QOL assessments in clinical trials to complement the risk–benefit judgment.

Longitudinal quality of life study in patients with metastatic gastric cancer

2005 ◽  
Vol 29 (11) ◽  
pp. 1113-1124 ◽  
Author(s):  
Franck Bonnetain ◽  
Olivier Bouché ◽  
Thierry Conroy ◽  
Patrick Arveux ◽  
Jean-Luc Raoul ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Metastatic Gastric Cancer ◽  
Life Study

scholarly journals Data on the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies: does it concern patients with gastric cancer?

2017 ◽  
Vol 30 (4) ◽  
pp. 203-206
Author(s):  
Malgorzata Skierucha ◽  
Karol Polom ◽  
Karol Rawicz-Pruszynski ◽  
Jerzy Mielko ◽  
Robert Sitarz ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Gastric Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Metastatic Gastric Cancer ◽  
Peritoneal Surface ◽  
Number Of Patients ◽  
Peritoneal Surface Malignancies

Abstract Introduction. So far there are no reports devoted exclusively to the quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in metastatic gastric cancer. Current literature concerning this issue was, thus, reviewed in order to: 1) search for such data concerning metastatic gastric cancer; 2) assess if the latest reviews evenly pertain to all peritoneal surface malignancies; and 3) conclude if they are a reliable source of data for patients with metastatic gastric cancer. Materials and Methods. The electronic PubMed/MEDLINE and EMBASE databases were retrieved for studies concerning the influence of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on quality of life in patients with metastatic gastric cancer and regardless of initial diagnosis. The data on the number of patients with particular tumours were analysed and the results were presented in the form of a table. Results. Approximately half of all patients encompassed by the reviews had a form of primary peritoneal surface malignancies. Within peritoneal metastases, the most numerous were colorectal (21-24%) and ovarian cancers (5-15%). Gastric cancers and sarcomas were the smallest defined subgroups (4% each). Conclusions. The promising outcomes in quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in primary peritoneal surface malignancies might differ from rarely reported ones in metastatic gastric cancer. The problem needs further, gastric cancer-devoted investigations.

Sign in / Sign up

Export Citation Format

Share Document